[et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.9.4″ custom_padding=”0px||0px||false|false”][et_pb_row _builder_version=”4.9.4″ _module_preset=”default” background_color=”#2b96cc” background_enable_image=”off” background_size=”initial” background_position=”top_left” background_repeat=”repeat-x”][et_pb_column type=”4_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” header_text_color=”#FFFFFF” hover_enabled=”0″ sticky_enabled=”0″]<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”2_5,3_5″ admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_image src=”https:\/\/www.gendiag.com\/wp-content\/uploads\/2016\/03\/slide15-900×435-960×435.jpg” title_text=”slide15-900×435-960×435″ align=”center” _builder_version=”4.9.4″ _module_preset=”default” hover_enabled=”0″ sticky_enabled=”0″][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”Text” _builder_version=”4.9.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]<\/p>\n
Gendiag<\/strong> devote its activity to pursue, analyze, and select highly competitive biotech projects for innovative markets. We focus in two major areas:<\/p>\n – Diagnostic tools, specially those ones obtained through genetic platforms and programmes.<\/p>\n – New therapeutic targets<\/p>\n Gendiag<\/strong> will contribute to R&D activities of the most promising projects, through close cooperation with the centre of excellence that generated the idea.<\/p>\n Gendiag<\/strong> will add value to projects requiring heavy investment, by completing early phases of development and by later on licensing-out to pharmaceutical companies.<\/p>\n Gendiag<\/strong> will market on its own or through alliances their own diagnostic platforms, those developed in cooperation with third parties, and those licensed-in<\/em>.<\/p>\n Gendiag<\/strong> offers professional advice to pharmaceutical companies in the areas of R&D and marketing of new products.<\/p>\n [\/et_pb_text][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” text_font_size=”28px” hover_enabled=”0″ custom_css_main_element=”color: #1e73be;|| text-align: left;|| font-family: Abril Fatface;|| font-weight: 400;|| font-style: normal;” sticky_enabled=”0″]<\/p>\n “Developing diagnostic tools… [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" CORE ACTIVITYGendiag devote its activity to pursue, analyze, and select highly competitive biotech projects for innovative markets. We focus in two major areas: – Diagnostic tools, specially those ones obtained through genetic platforms and programmes. – New therapeutic targets Gendiag will contribute to R&D activities of the most promising projects, through close cooperation with the […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":599,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"[vc_row][vc_column width=\"1\/3\"][vc_single_image image=\"235\" img_size=\"full\"][\/vc_column][vc_column width=\"2\/3\"][vc_column_text]\r\n Gendiag<\/strong> devote its activity to pursue, analyze, and select highly competitive biotech projects for innovative markets. We focus in two major areas:<\/p>\r\n - Diagnostic tools, specially those ones obtained through genetic platforms and programmes.<\/p>\r\n - New therapeutic targets<\/p>\r\n Gendiag<\/strong> will contribute to R&D activities of the most promising projects, through close cooperation with the centre of excellence that generated the idea.<\/p>\r\n Gendiag<\/strong> will add value to projects requiring heavy investment, by completing early phases of development and by later on licensing-out to pharmaceutical companies.<\/p>\r\n Gendiag<\/strong> will market on its own or through alliances their own diagnostic platforms, those developed in cooperation with third parties, and those licensed-in<\/em>.<\/p>\r\n Gendiag<\/strong> offers professional advice to pharmaceutical companies in the areas of R&D and marketing of new products.<\/p>\r\n[\/vc_column_text][vc_custom_heading text=\"Developing diagnostic tools...\r\n...applying personalized medicine.\" font_container=\"tag:h2|text_align:left|color:%231e73be\"][\/vc_column][\/vc_row]","_et_gb_content_width":""},"_links":{"self":[{"href":"https:\/\/www.gendiag.com\/en\/wp-json\/wp\/v2\/pages\/605"}],"collection":[{"href":"https:\/\/www.gendiag.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.gendiag.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.gendiag.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gendiag.com\/en\/wp-json\/wp\/v2\/comments?post=605"}],"version-history":[{"count":2,"href":"https:\/\/www.gendiag.com\/en\/wp-json\/wp\/v2\/pages\/605\/revisions"}],"predecessor-version":[{"id":2362,"href":"https:\/\/www.gendiag.com\/en\/wp-json\/wp\/v2\/pages\/605\/revisions\/2362"}],"up":[{"embeddable":true,"href":"https:\/\/www.gendiag.com\/en\/wp-json\/wp\/v2\/pages\/599"}],"wp:attachment":[{"href":"https:\/\/www.gendiag.com\/en\/wp-json\/wp\/v2\/media?parent=605"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
…applying personalized medicine.” <\/p>\n